X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pegfilgrastim (426) 426
humans (410) 410
filgrastim (352) 352
oncology (331) 331
index medicus (325) 325
chemotherapy (312) 312
female (266) 266
febrile neutropenia (264) 264
colony-stimulating factor (249) 249
neutropenia (244) 244
single-administration pegfilgrastim (226) 226
middle aged (223) 223
polyethylene glycols (212) 212
aged (196) 196
male (195) 195
daily filgrastim (194) 194
cancer (193) 193
granulocyte colony-stimulating factor - therapeutic use (189) 189
granulocyte colony-stimulating factor (187) 187
adult (182) 182
breast-cancer (154) 154
recombinant proteins (151) 151
multicenter (141) 141
neutropenia - chemically induced (139) 139
g-csf (133) 133
granulocyte colony-stimulating factor - administration & dosage (132) 132
breast cancer (112) 112
double-blind (112) 112
neutropenia - drug therapy (112) 112
neutropenia - prevention & control (108) 108
antineoplastic combined chemotherapy protocols - adverse effects (105) 105
hematology (105) 105
antineoplastic agents - adverse effects (98) 98
breast neoplasms - drug therapy (98) 98
pharmacology & pharmacy (94) 94
treatment outcome (93) 93
non-hodgkins-lymphoma (91) 91
medicine & public health (89) 89
granulocyte colony-stimulating factor - adverse effects (84) 84
neoplasms - drug therapy (80) 80
phase-iii (75) 75
retrospective studies (75) 75
antineoplastic combined chemotherapy protocols - therapeutic use (72) 72
health care sciences & services (71) 71
care and treatment (70) 70
chemotherapy-induced neutropenia (65) 65
recombinant proteins - therapeutic use (65) 65
research (64) 64
risk factors (64) 64
cell lung-cancer (58) 58
induced febrile neutropenia (56) 56
drug administration schedule (55) 55
antineoplastic combined chemotherapy protocols - administration & dosage (54) 54
recombinant proteins - administration & dosage (54) 54
young adult (53) 53
drug therapy (51) 51
dose-response relationship, drug (50) 50
cyclophosphamide (48) 48
nursing (48) 48
adjuvant chemotherapy (47) 47
analysis (47) 47
cycle (47) 47
risk (47) 47
aged, 80 and over (46) 46
rehabilitation (46) 46
antineoplastic agents - therapeutic use (44) 44
dose-intensity (44) 44
transplantation (44) 44
docetaxel (43) 43
growth-factors (43) 43
prophylaxis (43) 43
elderly-patients (41) 41
health aspects (41) 41
primary prophylaxis (40) 40
colony-stimulating factors (39) 39
hematology, oncology and palliative medicine (38) 38
lymphoma (38) 38
cyclophosphamide - administration & dosage (37) 37
lymphomas (37) 37
medicine, general & internal (37) 37
cancer patients (36) 36
guidelines (36) 36
original (36) 36
patients receiving chemotherapy (36) 36
prospective studies (36) 36
recombinant proteins - adverse effects (36) 36
safety (36) 36
filgrastim - therapeutic use (35) 35
granulocyte colony-stimulating factor - pharmacology (35) 35
granulocytes (35) 35
pain medicine (35) 35
rehabilitation medicine (35) 35
adolescent (34) 34
granulocyte colony-stimulating factor - pharmacokinetics (34) 34
neutrophils (34) 34
animals (33) 33
clinical trials (33) 33
granulocyte colony-stimulating factor - economics (33) 33
lymphoma, non-hodgkin - drug therapy (33) 33
mortality (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (562) 562
Spanish (6) 6
French (5) 5
Japanese (5) 5
Czech (4) 4
Polish (4) 4
Russian (3) 3
German (2) 2
Portuguese (2) 2
Lithuanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Supportive Care in Cancer, ISSN 0941-4355, 3/2014, Volume 22, Issue 3, pp. 667 - 677
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 2014, Volume 22, Issue 7, pp. 1833 - 1841
The objective of this study was to describe the incidence of grade 3/4 neutropenia, patterns of chemotherapy treatment, and granulocyte colony-stimulating... 
CHOP chemotherapy | Granulocyte colony-stimulating factor | Non-Hodgkin's lymphoma | Neutropenia | COLONY-STIMULATING FACTOR | SINGLE-ADMINISTRATION PEGFILGRASTIM | PHASE-III | RISK | LARGE-CELL LYMPHOMA | BREAST-CANCER | CANCER-PATIENTS | ONCOLOGY | FEBRILE NEUTROPENIA | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | ELDERLY-PATIENTS | DAILY FILGRASTIM | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Age Factors | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Dose-Response Relationship, Drug | Young Adult | Lymphoma, Non-Hodgkin - blood | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Prednisone - administration & dosage | Prednisone - adverse effects | Risk Factors | Rituximab | Neutropenia - drug therapy | Neutropenia - prevention & control | Vincristine - adverse effects | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Cyclophosphamide | Anthracyclines | Corticosteroids | Prednisone | Macrophage colony stimulating factor | Non-Hodgkin's lymphomas | Cancer | Lymphomas | Preventive medicine | Toxicity
Journal Article
British Journal of Haematology, ISSN 0007-1048, 08/2016, Volume 174, Issue 4, pp. 563 - 570
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2011, Volume 47, Issue 1, pp. 8 - 32
Journal Article
SUPPORTIVE CARE IN CANCER, ISSN 0941-4355, 04/2019, Volume 27, Issue 4, pp. 1449 - 1457
Journal Article
Journal Article
Journal Article
Wiener klinische Wochenschrift, ISSN 0043-5325, 4/2016, Volume 128, Issue 7, pp. 238 - 247
To describe the incidence of febrile neutropenia (FN) and use of pegfilgrastim in cancer patients with high overall risk of FN and to investigate the... 
Chemotherapy | Observational study | Pneumology/Respiratory System | Medicine & Public Health | Granulocyte colony-stimulating factor | Gastroenterology | Internal Medicine | Medicine/Public Health, general | Endocrinology | Neoplasms | Febrile neutropenia | ADJUVANT CHEMOTHERAPY | MORTALITY | PEGFILGRASTIM PRIMARY PROPHYLAXIS | COLONY-STIMULATING FACTOR | FILGRASTIM | DELIVERY | BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | IMPACT | CLINICAL-PRACTICE | PATIENTS RECEIVING CHEMOTHERAPY | Europe, Eastern - epidemiology | Neutropenia - epidemiology | Humans | Middle Aged | Granulocyte Colony-Stimulating Factor - standards | Chemotherapy-Induced Febrile Neutropenia - prevention & control | Male | Filgrastim | Incidence | Dose-Response Relationship, Drug | Aged, 80 and over | Recombinant Proteins - standards | Adult | Female | Chemotherapy-Induced Febrile Neutropenia - epidemiology | Polyethylene Glycols | Guideline Adherence - utilization | Risk Factors | Austria - epidemiology | Treatment Outcome | Recombinant Proteins - administration & dosage | Neoplasms - drug therapy | Neutropenia - prevention & control | Aged | Neoplasms - epidemiology | Granulocyte Colony-Stimulating Factor - administration & dosage | Lung cancer | Oncology, Experimental | Macrophage colony stimulating factor | Research | Drug therapy | Health aspects | Hyperthermia | Risk factors | Fever | Neutropenia | Cancer | Original
Journal Article